Immunic Therapeutics

1 Follower

About

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies

Dr. Hella Kohlhof
CSO
Dr. Manfred Groeppel
COO
Dr. Andreas Muehler
CMO
Glenn Whaley
Vice President Finance, Principal Financial and Accounting Officer

No teams yet!

No jobs yet!

Team announcement

Immunic announces formation of Scientific-Medical Advisory Board

Immunic announces formation of Scientific-Medical Advisory Board

Biopharmaceutical company Immunic, Inc. has announced the establishment of a Scientific-Medical Advisory Board, to advise the company’s management on the latest scientific developments and reviews relevant to the business. International doctors Fred D. Lublin, Bruce E. Sands, Jerrold R. Turner and Paul J. Utz will be the board’s inaugural members. "The establishment of a Scientific-Medical Advisory Board marks an important milestone for Immunic and we are honored to have such highly distinguished experts as our inaugural members," said Immunic Chief Executive Officer and President Daniel Vitt. "Together, their extensive knowledge, relationships and insights will be invaluable as we continue to advance our pipeline, and in particular our lead program, IMU-838, for which we recently reported very positive results from our phase 2 EMPhASIS trial in relapsing-remitting multiple sclerosis and which currently is in additional phase 2 trials for ulcerative colitis, primary sclerosing cholangitis and COVID-19." Dr. Fred D. Lublin is the Saunders Family Professor of Neurology and Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai in New York. He is a neuroimmunologist with particular expertise in multiple sclerosis, having served in a number of board positions for organizations focusing on treatment and research of the disease. Dr. Bruce E. Sands is Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai in New York. He is an experienced researcher into Crohn's disease and ulcerative colitis, who has served as Chair of the Clinical Research Alliance of the Crohn's Foundation of America, Chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association, and Chair of the International Organization for the Study of IBD. Dr. Jerrold R. Turner is a Professor of Pathology and Medicine at Harvard Medical School, and also a Senior Pathologist in the Department of Pathology at Brigham and Women's Hospital. He is the Founding Editor-In-Chief of Cellular and Molecular Gastroenterology and Hepatology, the scientific journal of the American Gastroenterological Association, and has served as the Associate Editor of Gastroenterology, the American Journal of Pathology, and Laboratory Investigation. Dr. Paul J. Utz is a Professor of Medicine – Immunology & Rheumatology at the Stanford University School of Medicine. He is a leading expert in the study of human and murine autoantibodies and autoantigens, apoptosis signaling pathways, animal models of autoimmunity, proteomics and multiplexed assay development for biomarker discovery, and the Stanford Associate Dean for Medical Student Research.

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.